CoChat

Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial

Open access
Kim, Edward S., Velcheti, Vamsidhar, Mekhail, Tarek, Yun, Cindy, Shagan, Sarah M., Hu, Sylvia, Chae, Young Kwang, Leal, Ticiana A., Dowell, Jonathan E., Tsai, Michaela L., Dakhil, Christopher S. R., Stella, Philip, Jin, Yanling, Shames, David S., Schleifman, Erica, Fabrizio, David A., Phan, See, Socinski, Mark A. · 2022 · Nature Medicine
Cited by 180

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Tumor mutational burden (TMB) in circulating tumor DNA (ctDNA) has shown promise in predicting benefit from PD-L1/PD-1 inhibitors in retrospective studies. Aiming to assess blood TMB (bTMB) prospectively, we conducted B-F1RST (NCT02848651), an open-label, phase 2 trial that evaluated bTMB as a predictive biomarker for first-line atezolizumab monotherapy in locally advanced or metastatic stage IIIB–IVB non-small cell lung cancer (n = 152). The co-primary endpoints were investigator-assessed objective response rate (ORR) per RECIST version 1.1 and investigator-assessed progression-free survival (PFS) between high and low bTMB subgroups at the pre-defined bTMB ≥ 16 (14.5 mutations per megabase) cutoff. Secondary endpoints included investigator-assessed PFS, overall survival (OS) and duration of response at various bTMB cutoffs, as well as safety. Investigator-assessed PFS in the bTMB ≥ 16 versus bTMB < 16 groups was not statistically significant. However, bTMB ≥ 16 was associated with higher ORR, and ORR improved as bTMB cutoffs increased. No new safety signals were seen. In exploratory analyses, patients with maximum somatic allele frequency (MSAF) < 1% had higher ORR than patients with MSAF ≥ 1%. However, further analysis showed that this effect was driven by better baseline prognostics rather than by MSAF itself. At 36.5-month follow-up, an exploratory analysis of OS found that bTMB ≥ 16 was associated with longer OS than bTMB < 16. Further study and assay optimization will be required to develop bTMB as a predictive, standalone biomarker of immunotherapy or for use in conjunction with other biomarkers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01754-x

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 180

Metadata

Authors
Kim, E. S., Velcheti, V., Mekhail, T., Yun, C., Shagan, S. M., Hu, S., Chae, Y. K., Leal, T. A., Dowell, J. E., Tsai, M. L., Dakhil, C. S. R., Stella, P., Jin, Y., Shames, D. S., Schleifman, E., Fabrizio, D. A., Phan, S., & Socinski, M. A.
Venue
Nature Medicine
Published
2022-04-14
Volume
28
Issue
5
Pages
939-945
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4224035333
Cited by
180
References
5
FWCI
13.41
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. https://app.cochat.ai/papers/10.1038/s41591-022-01754-x
The paper
Kim, E. S., Velcheti, V., Mekhail, T., Yun, C., Shagan, S. M., Hu, S., Chae, Y. K., Leal, T. A., Dowell, J. E., Tsai, M. L., Dakhil, C. S. R., Stella, P., Jin, Y., Shames, D. S., Schleifman, E., Fabrizio, D. A., Phan, S., & Socinski, M. A. (2022). Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nature Medicine. https://doi.org/10.1038/s41591-022-01754-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.